JP2025503451A - 炭酸脱水酵素ｉｘリガンド - Google Patents

炭酸脱水酵素ｉｘリガンド Download PDF

Info

Publication number
JP2025503451A
JP2025503451A JP2024536171A JP2024536171A JP2025503451A JP 2025503451 A JP2025503451 A JP 2025503451A JP 2024536171 A JP2024536171 A JP 2024536171A JP 2024536171 A JP2024536171 A JP 2024536171A JP 2025503451 A JP2025503451 A JP 2025503451A
Authority
JP
Japan
Prior art keywords
group
compound
amino
residue
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503451A5 (https=
Inventor
フランク・オスターカンプ
アイレーン・ホーネ
マティーアス・パシュケ
ディルク・ツボラルスキ
エバーハルト・シュナイダー
クリスティアン・ハーゼ
ヤン・ウンゲヴィス
アンネ・ブレーデンベック
クリスティアーネ・スマーリング
ウルリヒ・ライネケ
イーナ・ヴィルケニング
Original Assignee
スリービー・ファーマシューティカルズ・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スリービー・ファーマシューティカルズ・ゲーエムベーハー filed Critical スリービー・ファーマシューティカルズ・ゲーエムベーハー
Publication of JP2025503451A publication Critical patent/JP2025503451A/ja
Publication of JP2025503451A5 publication Critical patent/JP2025503451A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024536171A 2021-12-17 2022-12-19 炭酸脱水酵素ｉｘリガンド Pending JP2025503451A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP2021086592 2021-12-17
EPPCT/EP2021/086592 2021-12-17
EPPCT/EP2022/054857 2022-02-25
EP2022054857 2022-02-25
EPPCT/EP2022/057170 2022-03-18
EP2022057170 2022-03-18
EP2022057840 2022-03-24
EPPCT/EP2022/057840 2022-03-24
EP2022067424 2022-06-24
EPPCT/EP2022/067424 2022-06-24
EPPCT/EP2022/079606 2022-10-24
EP2022079606 2022-10-24
EP2022081674 2022-11-11
EPPCT/EP2022/081674 2022-11-11
PCT/EP2022/086632 WO2023111350A2 (en) 2021-12-17 2022-12-19 Carbonic anhydrase ix ligands

Publications (2)

Publication Number Publication Date
JP2025503451A true JP2025503451A (ja) 2025-02-04
JP2025503451A5 JP2025503451A5 (https=) 2025-12-16

Family

ID=84981172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536171A Pending JP2025503451A (ja) 2021-12-17 2022-12-19 炭酸脱水酵素ｉｘリガンド

Country Status (13)

Country Link
US (1) US20250339569A1 (https=)
EP (1) EP4448544A2 (https=)
JP (1) JP2025503451A (https=)
KR (1) KR20240133798A (https=)
AR (1) AR128023A1 (https=)
AU (1) AU2022410422B2 (https=)
CA (1) CA3242384A1 (https=)
CL (1) CL2024001830A1 (https=)
IL (1) IL313536A (https=)
MA (1) MA66591A1 (https=)
MX (1) MX2024007454A (https=)
TW (1) TW202340226A (https=)
WO (1) WO2023111350A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243979A1 (en) * 2022-02-11 2025-04-30 C-Biomex Co., Ltd. Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
AR133015A1 (es) * 2023-06-20 2025-08-20 Debiopharm Int Sa Compuesto radiomarcado para su uso en un método de tratamiento de enfermedades con anhidrasa carbónica ix positiva
WO2025023747A1 (ko) * 2023-07-25 2025-01-30 (주)씨바이오멕스 탄산탈수소효소 ⅸ를 표적으로 하는 펩타이드 구조체 및 이들의 용도
CN120943901A (zh) * 2025-05-29 2025-11-14 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
WO2012016713A1 (en) 2010-08-05 2012-02-09 Ruprecht-Karls-Universität Heidelberg Tumour targeting with polypeptides
WO2013172954A1 (en) * 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
TW201919682A (zh) * 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Ｎｒｆ２路徑的新穎化合物
WO2019096867A1 (en) 2017-11-14 2019-05-23 Debiopharm Research & Manufacturing S.A. Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b
WO2020084305A1 (en) * 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900525D0 (en) * 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
JP7801207B2 (ja) * 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
TWI765195B (zh) 2019-11-22 2022-05-21 行政院原子能委員會核能研究所 雙靶向碳酸酐酶第九型複合物及其造影劑

Also Published As

Publication number Publication date
WO2023111350A2 (en) 2023-06-22
AR128023A1 (es) 2024-03-20
MX2024007454A (es) 2024-09-02
WO2023111350A3 (en) 2023-07-27
KR20240133798A (ko) 2024-09-04
AU2022410422B2 (en) 2026-01-08
US20250339569A1 (en) 2025-11-06
EP4448544A2 (en) 2024-10-23
MA66591A1 (fr) 2025-05-30
CA3242384A1 (en) 2023-06-22
IL313536A (en) 2024-08-01
TW202340226A (zh) 2023-10-16
AU2022410422A1 (en) 2024-07-04
CL2024001830A1 (es) 2024-12-06

Similar Documents

Publication Publication Date Title
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP7801207B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
KR20230129260A (ko) 섬유모세포 활성화 단백질 리간드를 포함하는 화합물및 그의 용도
JP2025503451A (ja) 炭酸脱水酵素ｉｘリガンド
EP3763726A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
CN118591549A (zh) 碳酸酐酶ix配位体
US20260083865A1 (en) Prostate specific membrane antigen (psma) ligands and use thereof
EP4610269A1 (en) Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use
WO2025109003A1 (en) P-cadherin ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208